Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951140B2 · kind B2 · utility
6Cited by
246References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2023 |
| Grant date | Apr 9, 2024 |
| Priority date | — |
| Expiry date | May 4, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.